These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 33183015)

  • 1. A heavily pre-treated adenocarcinoma patient with EGFR exon 20 insertion mutation responded to pembrolizumab plus nab-paclitaxel/bevacizumab: a case report.
    Huang X; Yang Y; Wang P; Han-Zhang H; Ding L
    Ann Palliat Med; 2021 Jun; 10(6):6997-7002. PubMed ID: 33183015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab and chemotherapy in non-small cell lung cancer with EGFR ex20ins mutation: A case report.
    Zhang M; Nie L; Cheng Y
    Thorac Cancer; 2021 Oct; 12(20):2803-2806. PubMed ID: 34382340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
    Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.
    Han H; Zhang X; Liu X; Zhao J; Zhang J; Zhang J; Zhu H; Jiao S; Tang H
    Medicine (Baltimore); 2023 Dec; 102(52):e36667. PubMed ID: 38206746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
    Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
    Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib.
    Fan Y; Qin J; Han N; Lu H
    Ann Palliat Med; 2022 Apr; 11(4):1582-1588. PubMed ID: 34118831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable response to immunotherapy plus chemotherapy in a patient with untreated, brain-metastatic, EGFR exon 20 insertion mutation lung adenocarcinoma: A case report.
    Nong J; Gu Y; Yao S; Zhang Y
    Medicine (Baltimore); 2021 Jul; 100(29):e26650. PubMed ID: 34398022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant immunotherapy plus chemotherapy achieved pathologic complete response in stage IIIB lung adenocarcinoma harbored EGFR G779F: a case report.
    Wang Y; Yang X; Tian X; Jia Z; Bing Z; Cao L; Gao C; Cao Z; Li S; Liang N
    Ann Palliat Med; 2020 Nov; 9(6):4339-4345. PubMed ID: 33183013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy.
    Trummer A; Bethge A; Dickgreber N; Dittrich I; Golpon H; Hoffknecht P; Overbeck TR; Wesseler C; Reck M
    Lung Cancer; 2022 Dec; 174():141-145. PubMed ID: 36402005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with
    Reck M; Shankar G; Lee A; Coleman S; McCleland M; Papadimitrakopoulou VA; Socinski MA; Sandler A
    Expert Rev Respir Med; 2020 Feb; 14(2):125-136. PubMed ID: 31829747
    [No Abstract]   [Full Text] [Related]  

  • 11. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
    Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Erlotinib plus Bevacizumab Therapy for Postoperative Recurrence of Adenosquamous Cell Carcinoma Harboring EGFR Mutation-A Case Report].
    Kamiyoshihara M; Yazawa T; Igai H; Matsuura N; Ohsawa F; Furusawa S
    Gan To Kagaku Ryoho; 2021 Jun; 48(6):841-843. PubMed ID: 34139736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
    Wu JY; Yu CJ; Shih JY
    Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non-small cell lung cancer.
    Pan B; Liang J; Shi H; Rao K; Guo W; Zhan C
    Thorac Cancer; 2023 Nov; 14(33):3247-3258. PubMed ID: 37795778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
    Miyauchi E; Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T;
    Jpn J Clin Oncol; 2015 Jul; 45(7):670-6. PubMed ID: 25877748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients.
    Honma HN; Perroud MW; Leme MS; Barbeiro AS; Saad BA; Morcillo AM; Vassallo J; Costa DB; Zambon L
    Target Oncol; 2014 Dec; 9(4):389-94. PubMed ID: 24793378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobocertinib (TAK-788): A Targeted Inhibitor of
    Gonzalvez F; Vincent S; Baker TE; Gould AE; Li S; Wardwell SD; Nadworny S; Ning Y; Zhang S; Huang WS; Hu Y; Li F; Greenfield MT; Zech SG; Das B; Narasimhan NI; Clackson T; Dalgarno D; Shakespeare WC; Fitzgerald M; Chouitar J; Griffin RJ; Liu S; Wong KK; Zhu X; Rivera VM
    Cancer Discov; 2021 Jul; 11(7):1672-1687. PubMed ID: 33632773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel
    Zhi X; Luo J; Li W; Wang J; Wang Y; Cai Y; Yan X
    Front Oncol; 2021; 11():733276. PubMed ID: 34760695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
    Rosell R; Dafni U; Felip E; Curioni-Fontecedro A; Gautschi O; Peters S; Massutí B; Palmero R; Aix SP; Carcereny E; Früh M; Pless M; Popat S; Kotsakis A; Cuffe S; Bidoli P; Favaretto A; Froesch P; Reguart N; Puente J; Coate L; Barlesi F; Rauch D; Thomas M; Camps C; Gómez-Codina J; Majem M; Porta R; Shah R; Hanrahan E; Kammler R; Ruepp B; Rabaglio M; Kassapian M; Karachaliou N; Tam R; Shames DS; Molina-Vila MA; Stahel RA;
    Lancet Respir Med; 2017 May; 5(5):435-444. PubMed ID: 28408243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report.
    Inagaki Y; Tamiya A; Matsuda Y; Azuma K; Adachi Y; Enomoto T; Kouno S; Taniguchi Y; Saijo N; Okishio K; Atagi S
    Medicine (Baltimore); 2020 Oct; 99(42):e22628. PubMed ID: 33080698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.